Can a biologic drug help peanut allergy sufferers tolerate nuts?
NCT ID NCT07015996
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding tezepelumab (a biologic drug) to peanut oral immunotherapy (OIT) helps people with peanut allergy tolerate more peanut without symptoms. 62 participants aged 12 to 55 will first receive tezepelumab or placebo alone, then both groups undergo peanut OIT for 56 weeks, followed by a 12-week withdrawal period. The main goal is to see if participants can eat a cumulative dose of 4000 mg of peanut protein without symptoms after stopping all treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tezepelumab (a biologic drug) and peanut oral immunotherapy (gradual exposure to peanut protein)
- What this could lead to
- If successful, this could point toward a treatment that allows people with peanut allergy to safely eat small amounts of peanut without severe reactions.
- What could go wrong
- This is an early Phase 2 proof-of-concept trial with only 62 participants, so results may not apply to everyone. There is also a risk of allergic reactions during the oral immunotherapy phase.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEANUT ALLERGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arkansas Children's Hospital Research Institute: Department of Pediatrics, Allergy & Immunology
NOT_YET_RECRUITINGLittle Rock, Arkansas, 72202, United States
-
Boston Children's Hospital: Allergy and Asthma Program
NOT_YET_RECRUITINGBoston, Massachusetts, 02115, United States
-
Cincinnati Children's Hospital Medical Center: Division of Allergy and Immunology
RECRUITINGCincinnati, Ohio, 45229, United States
-
Icahn School of Medicine at Mount Sinai: Department of Pediatrics Allergy & Immunology
NOT_YET_RECRUITINGNew York, New York, 10029-6574, United States
-
Johns Hopkins Children's Center: Department of Allergy & Immunology
NOT_YET_RECRUITINGBaltimore, Maryland, 21287, United States
-
Massachusetts General Hospital: Department of Medicine: Allergy & Clinical Immunology Unit
NOT_YET_RECRUITINGBoston, Massachusetts, 02114, United States
-
North Carolina Children's Hospital: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology
RECRUITINGChapel Hill, North Carolina, 27599, United States
-
The University of Michigan: Division of Allergy and Clinical Immunology
NOT_YET_RECRUITINGAnn Arbor, Michigan, 48105, United States
-
University of California, Los Angeles: Department of Medicine, Division of Clinical Immunology and Allergy
NOT_YET_RECRUITINGLos Angeles, California, 90095, United States
-
University of Texas Southwestern Medical Center: Division of Allergy and Immunology
NOT_YET_RECRUITINGDallas, Texas, 75390-9063, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peanut allergy cure in sight? trial tests tolerance in teens
- Can a shot tame peanut allergies? small study tests xolair
- Can allergy drugs help kids tolerate peanut and more?
- Peanut allergy patch enters human safety trials
- Could supermarket peanuts and milk cure food allergies? new study investigates.
- New daily oral treatment aims to tame peanut allergy